Loading
Whether a breast cancer's cells carry receptors for oestrogen (ER) and progesterone (PR). If they do, the cancer is fed by these hormones and can be treated by blocking them; about 70% of breast cancers are hormone receptor-positive.
Measured by immunohistochemistry on every breast cancer; ≥1% of nuclei staining counts as positive (1-10% is 'ER-low' and behaves more like negative). HR-positive/HER2-negative disease receives endocrine therapy (tamoxifen, aromatase inhibitors, SERDs) with CDK4/6 inhibitors in high-risk or metastatic settings; HR status combined with HER2 defines the four clinical subtypes (HR+/HER2−, HER2+, triple-negative). Endometrial, ovarian and some other cancers are also ER/PR tested. Loss of ER at relapse and ESR1 mutations mark endocrine resistance.
In plain words · The hormone switch that drives most breast cancers. Blocking or destroying it is the oldest and most effective targeted therapy.
Showing the target this term concerns: Estrogen receptor (ERα).
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares How ER and PR are scored on a breast report (Allred score, H score, and why PR is not a UK core item), Receptor conversion: when the receptors change between the primary and a recurrence, Grade, stage and receptor status: three different things on one breast report, HER2-positive (IHC 3+ or ISH-amplified).
Shares How ER and PR are scored on a breast report (Allred score, H score, and why PR is not a UK core item), Receptor conversion: when the receptors change between the primary and a recurrence, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Grade, stage and receptor status: three different things on one breast report, Histopathology & immunohistochemistry, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Selective oestrogen receptor degrader (SERD), ER status (oestrogen receptor by IHC), Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), Histopathology & immunohistochemistry, HR-positive / HER2-negative breast cancer.
Shares Grade, stage and receptor status: three different things on one breast report, Male breast cancer, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Selective oestrogen receptor degrader (SERD), Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), Breast cancer (all types), Triple-negative breast cancer (TNBC).